AzTrials
AzTrials

Cardiac Surgical ProceduresTELUSPORENCT04760340

TELUS in Cardiac Surgery Patients. Effect of CPB and Relation to Postoperative Events (PORE)Events.

An observational study of Cardiac Surgical Procedures, run by Clinique du Millenaire.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Transesophageal Lung ultrasound (TELUS) was described for the first time in 2016. The clinical significance and benefits for the patient of the results of a TELUS examination has not been investigated to date. Read more about this study

Who is it for?
Any age
Conditions the study is for
Cardiac Surgical Procedures
How many people
120 participants
Where
No sites listed yet
Study dates
1 Mar 2021to 1 Aug 2021
How long will I take part?
6 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Adult cardiac surgery with CPB and TEE monitoring

Who may be able to join

  • Adult cardiac surgery patients with a comprehensive TEE and TELUS examination pre CPB will be included.

Who cannot join

  • Previous lung surgery
  • Previous thoracic radiation therapy for cancer (lung, breast, lymphoma or other)
  • Mitral valve surgery using a mini thoracotomy and video assistance
  • Use of an ultrafiltration device during CPB
  • Mechanical ventilation initiated before arrival in the OR.

Trial locations and contacts

No sites are listed yet.

Philippe BURTIN, MD contact

+33622745310

philippe.burtin@cegetel.net

About this study

Official title: TELUS in Cardiac Surgery Patients. Effect of CPB and Relation to Postoperative Events (PORE).

Transesophageal Lung ultrasound (TELUS) was described for the first time in 2016. The clinical significance and benefits for the patient of the results of a TELUS examination has not been investigated to date.

Since all cardiac surgery with CPB cases in adult patients are performed using a TEE probe to monitor cardiac function, a concomitant TELUS examination is possible in all cases.

Read more

The study seeks to describe the incidence and severity of the modifications of the aeration of both lungs assessed by TELUS in the perioperative period of adult cardiac surgery and to establish the relation of the TELUS findings with the occurence of postoperative respiratory events (PORE).

Eventually, the study will also provide results about the interobserver variation of the TELUS examination for which there no reference to date.

Read the detailed description

Trans Esophageal Lung Ultrasound (TELUS) score in Cardiac surgery (CS) patients.

Effect of CPB and relationship between changes on TELUS score and postoperative respiratory events (PORE).

International recommendations for LUS assessment are available as well as the LUS methodology and nomenclature are widely accepted (1). Additionally, transthoracic LUS demonstrated a predictive value for postoperative pulmonary complication in non-cardiac surgery (2).

More recently, the Trans Esophageal Lung Ultrasound (TELUS) has been described (3).

Adult cardiac surgery patients are at special risk of perioperative respiratory complications including pulmonary edema, Acute Respiratory Distress Syndrome (ARDS), prolonged ventilation and non-invasive ventilation (NIV), tracheotomy and pulmonary infection (4). These complications are responsible for a substantial part of the perioperative case fatality rate. Prevention of these complications by using low tidal volume and an open lung strategy has failed to significantly reduce the incidence of postoperative respiratory events (PORE) (5).

A worsening of the TELUS imaging occurs after CPB when compared with pre CPB imaging has been observed. These observations are consistent with the increase of extra vascular lung water during CPB along with specific effects of CPB on lung vessels (6).

Our primary hypothesis is that CPB induced changes in the TELUS imaging score. Our secondary hypothesis is that magnitude of modifications are related to post-operative respiratory events (PORE) and postoperative complications. The TELUS modifications could have a predictive value for post-operative PORE and thus may help to discriminate patients at risk for PORE.

Objectives 1 - Primary objective :

1 - 1 Describing the incidence and severity of the changes in TELUS imaging between the pre CPB and the post CPB assessment.

  1. - 2 Describing the relation of the post CPB TELUS findings and the occurrence of PORE during hospital stay. The primary end-point will be a composite of prolonged NIV (> 12 hours) and / or return to Mechanical Ventilation (MV) after a first successful extubation and / or ICU readmission after a first successful ICU discharge. The secondary endpoints will be : total MV duration, total ICU LOS, total hospital LOS, need for tracheotomy, death from all cause.
  2. - Secondary objectives

2 - 1 pre / post CPB TELUS imaging will be assessed by a second examiner allowing us to calculate for the first time the pre / post CPB inter-observer variability of TELUS imaging in adult cardiac surgery. Intra observer variability will be assessed as well.

2 - 2 As a standard transthoracic LUS is performed in all CS patients at admission in the ICU post-operatively, the respective relation of the admission LUS and post-CPB TELUS scores with the first PaO2 / fraction of inspired oxygen (FiO2) (P/F) ratio obtained at admission in the ICU.

Methods This is a single center, non-interventional, observational and prospective study.

The study will be registered at Clinical trials.gov. The study will be conducted according to the STROBE guidelines.

All patients will be informed orally during the mandatory pre-anesthesia interview usually performed the day before surgery. A written information document will be given preoperatively to each patient and filed. Patients will be included at the start of the pre-CPB TEE examination.

  1. - Anesthesia Briefly, Two standard anesthesia protocols are in use in the institution. Anesthesia will be maintained either with Total Intravenous Anesthesia (TIVA) (continuous infusion of propofol and remifentanil with titration to keep the Bispectral index (BIS) values between 50 and 60) or inhalation anesthesia (remifentanil infusion and continuous sevoflurane inhalation including during CPB). Full muscle relaxation will be obtained with standard doses of atracurium or cisatracurium. Lungs will be ventilated with a low tidal volume of 6 ml.kg-1 (IBW). Standard arterial and central venous catheterization will be inserted in all patients. Hemodynamic monitoring will be performed with a Flotrac sensor and EV1000 monitor (EDWARDS Life Science - Irvine - USA). A continuous airway pressure of 5 cmH2O will be maintained during CPB. After skin closure, patients will be transferred to the ICU and anesthesia infusions will be discontinued after 2 hours if extubation criteria are met : bleeding < 200 ml, normal ECG recording, normal gas exchange, hemodynamic stability with or without low dose vasopressive support (norepinephrine < 100 µg.kg-1.h-1 IV).
  2. - CPB CPB will be performed according to institutional standard of care and international guidelines (7) CPB flow will be performed using a centrifugal pump after caval and aortic canulation. In some cases femoral or bicaval canulation will be used. Full anticoagulation will be performed with unfractioned Heparin with POC monitoring (target Activated clotting Time (ACT) : 480 sec) according to guidelines. A minimum of 2.5 l/min CPB flow will be maintained. Cardioplegia will be performed by antegrade and/or retrograde normothermic cardioplegia according to the type of surgery. Centrifugation of the residual volume of the CPB circuit at the end of the procedure will be performed and re-transfused to the patient.
  3. - TEE Comprehensive TEE will be performed in anesthetized patients before skin incision (preCPB) and after chest closure (post CPB) using a GE Vivid S7 ultrasound system (GE Healthcare, Chicago IL, USA). TEE examination will be performed according to our standard procedure, reporting and archiving. Pre and post CPB LV function indices (LVEF, E wave, A wave velocities, E' and S'Lat velocities, quantification of Mitral Regurgitation (MR) if present).
  4. - TELUS Using the same imaging system, TELUS will be performed pre and post CPB according to the method described by previous authors (3). Sagittal (90°) mid-esophageal view and rotation of the probe will allow right lung interrogation of the anterior (60° rotation), lateral (90° rotation) and posterior (120° rotation) zones and left lung interrogation of the anterior (300° rotation), lateral (270° rotation) and posterior (240° rotation) zones. For each zone a TELUS score will be defined according to standard definitions : TELUS 0 : presence of A lines, TELUS 1 : less than 3 B lines , TELUS 2 : more than 3 B lines or confluent B lines, TELUS 3 : sub pleural condensation. Additionally, immediate findings (Pleural effusion, Alveolar consolidation, Pneumothorax) will be recorded. Thus, the maximum LUS score per lung will be 9 and the maximum LUS score per patient will be 18.
  5. - LUS A transthoracic LUS examination will be performed immediately after arrival in the ICU (standard routine practice). For each lung the anterior, lateral and posterior zones will be interrogated. For each zone a LUS score will be defined according to standard definitions : LUS 0 : presence of A lines, LUS 1 : less than 3 B lines , LUS 2 : more than 3 B lines or confluent B lines, LUS 3 : sub pleural condensation. Additionally, immediate findings (Pleural effusion, Alveolar consolidation, Pneumothorax) will be recorded. Thus the maximum LUS score per lung will be 9 and the maximum LUS score per patient will be 18.
  6. - Biological data Arterial blood gas are routinely drawn as a standard practice : a - After anesthesia and before skin incision b -Immediately after obtaining the CPB full flow c - Every 20 - 25 min during CPB d -5 - 10 min after protamine injection. e - 15 min after arrival in the ICU a,d, and e blood gases results will be recorded and P/F ratio will be calculated. Troponin will be measured (ROCHE Diagnostics, Basel, Switzerland) in all patients at H24 as an institution standard practice.
  7. - Recorded data All data will be recorded in an anonymous database (EXCEL worksheet). The recorded data will be:
  • Hospital file number, initials, Demographic and procedural data, comorbidities, medications, baseline hematocrit and creatinine level
  • Pre CPB TELUS data and score, TEE data, P/F, MAP, SAP, DAP, Heart Rate, O2 arterial saturation
  • post CPB TELUS data and score, TEE data, P/F, MAP, SAP, DAP, Heart Rate, O2 arterial saturation, total IV fluid balance during CPB.
  • LUS data and score, P/F after arrival in the ICU
  • Post-operative respiratory events (PORE) : time to extubation (hours), total time on NIV (hours), return to mechanical ventilation (intubation), total time on ventilation (hours),Tracheotomy and duration (hours), length of stay (LOS) in ICU (hours), pneumothorax after removal of chest tubes, pleural effusion, pneumonia (≥ 2 criteria including fever> 38.5 ° C or T <36 ° C, leukocytosis> 109/ L , purulent tracheal secretions and the appearance or persistence of an infiltrate on the CXR), atelectasis, pulmonary embolism, NO inhalation and total duration (hours), ARDS (Berlin definition), sternal wound infection, in-hospital LOS (days)
  • Other in-hospital complications : cardiac ischemia, congestive heart failure, ventricular dysrhythmia, new onset of atrial fibrillation (NOAF), Acute kidney failure (AKI), Renal replacement therapy (RRT) and total duration (hours), cerebral ischemia, sepsis from other origin than the lungs, blood transfusion (units count), ICU Readmission, death from all cause.
  1. - Statistical analysis As there is no previous study that have observed TELUS during CPB in CS, sample size calculation cannot be done because mean score and standard deviation are not known. All patients with complete TELUS and LUS examinations during a four month period will be included.

Inter-observer variability will be assessed using the Bland Altman method (8), Lin test (9), and weighted kappa test (10).

Qualitative variables will be expressed as an absolute value and percentage. Quantitative variables will be expressed as a mean and Standard deviation (SD) or median and interquartile range depending on the normality of the data distribution.

Comprehensive descriptive statistics. Comparisons will be made between the pre and post CPB TELUS recordings for demographic, procedural and biological data.

Two groups will be defined according to the value of the PostCPB TELUS Score. Group HITELUS with the patients with TELUS score of 12 or higher. Group LOTELUS with the patients with TELUS score under 12. The two groups will be compared for the incidence of the primary and secondary outcomes and for all comorbidities and procedural variables.

Comparisons will be made between the post CPB TELUS and ICU LUS recordings for demographic, procedural and biological data.

A composite score of PORE will be built. To determine TELUS / LUS variables associated with PORE occurrence, multivariate logistic regression will be performed.

To determine the predictive performance of TELUS / LUS scores for RE occurrence ROC curves will be generated with calculation of Area Under the Curve (AUC) with confidence intervals, Se, Sp, positive and Negative predictive values (PPV and NPV), Youden index values.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Extubation time (minutes)

    Time from ICU admission to first postoperative successful extubation.

    Measured: 150 days

  2. Total postoperative NIV time (hours)

    Total time on NIV during postoperative hospital stay

    Measured: 150 days

  3. Total MV time (hours)

    Total time on MV during postoperative hospital stay

    Measured: 150 days

  4. Total ICU stay (hours)

    Length of stay in the icu during hospital stay

    Measured: 150 days

Secondary outcomes (3)
  1. Pre CPB TELUS score (n)

    Cumulative score of the TELUS grading for the 3 zones of each lung (Min : 0 ; Max : 18) calculated before CPB

    Measured: 1 day

  2. Post CPB TELUS score (n)

    Cumulative score of the TELUS grading for the 3 zones of each lung (Min : 0 ; Max : 18) calculated after CPB

    Measured: 1 day

  3. Post CPB P/F ratio (mmHg)

    Ratio between PaO2 (mmHg) and FiO2 (%)

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2021
  2. Study start1 Mar 2021 (estimated)
  3. Primary completion1 Jul 2021 (estimated)
  4. Study completion1 Aug 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
120 participants (estimated)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04760340
Sponsor's protocol ID
Akomé - 01 - 2021
Acronym
TELUSPORE
Status last verified
Feb 2021
First submitted
24 Jan 2021
Last updated
18 Feb 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, Melniker L, Gargani L, Noble VE, Via G, Dean A, Tsung JW, Soldati G, Copetti R, Bouhemad B, Reissig A, Agricola E, Rouby JJ, Arbelot C, Liteplo A, Sargsyan A, Silva F, Hoppmann R, Breitkreutz R, Seibel A, Neri L, Storti E, Petrovic T; International Liaison Committee on Lung Ultrasound (ILC-LUS) for International Consensus Conference on Lung Ultrasound (ICC-LUS). International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012 Apr;38(4):577-91. doi: 10.1007/s00134-012-2513-4. Epub 2012 Mar 6.

    PubMed 22392031
  • Zieleskiewicz L, Papinko M, Lopez A, Baldovini A, Fiocchi D, Meresse Z, Boussuges A, Thomas PA, Berdah S, Creagh-Brown B, Bouhemad B, Futier E, Resseguier N, Antonini F, Duclos G, Leone M. Lung Ultrasound Findings in the Postanesthesia Care Unit Are Associated With Outcome After Major Surgery: A Prospective Observational Study in a High-Risk Cohort. Anesth Analg. 2021 Jan;132(1):172-181. doi: 10.1213/ANE.0000000000004755.

    PubMed 32224722
  • Cavayas YA, Girard M, Desjardins G, Denault AY. Transesophageal lung ultrasonography: a novel technique for investigating hypoxemia. Can J Anaesth. 2016 Nov;63(11):1266-76. doi: 10.1007/s12630-016-0702-2. Epub 2016 Jul 29.

    PubMed 27473720
  • Litwinowicz R, Bartus K, Drwila R, Kapelak B, Konstanty-Kalandyk J, Sobczynski R, Wierzbicki K, Bartus M, Chrapusta A, Timek T, Bartus S, Oles K, Sadowski J. In-hospital mortality in cardiac surgery patients after readmission to the intensive care unit: a single-center experience with 10,992 patients. J Cardiothorac Vasc Anesth. 2015;29(3):570-5. doi: 10.1053/j.jvca.2015.01.029. Epub 2015 Jan 16.

    PubMed 26009285
  • Lagier D, Fischer F, Fornier W, Huynh TM, Cholley B, Guinard B, Heger B, Quintana G, Villacorta J, Gaillat F, Gomert R, Degirmenci S, Colson P, Lalande M, Benkouiten S, Minh TH, Pozzi M, Collart F, Latremouille C, Vidal Melo MF, Velly LJ, Jaber S, Fellahi JL, Baumstarck K, Guidon C; PROVECS Study Group. Effect of open-lung vs conventional perioperative ventilation strategies on postoperative pulmonary complications after on-pump cardiac surgery: the PROVECS randomized clinical trial. Intensive Care Med. 2019 Oct;45(10):1401-1412. doi: 10.1007/s00134-019-05741-8. Epub 2019 Oct 1.

    PubMed 31576435
  • Huffmyer JL, Groves DS. Pulmonary complications of cardiopulmonary bypass. Best Pract Res Clin Anaesthesiol. 2015 Jun;29(2):163-75. doi: 10.1016/j.bpa.2015.04.002. Epub 2015 Apr 23.

    PubMed 26060028
  • Authors/Task Force Members; Kunst G, Milojevic M, Boer C, De Somer FMJJ, Gudbjartsson T, van den Goor J, Jones TJ, Lomivorotov V, Merkle F, Ranucci M, Puis L, Wahba A; EACTS/EACTA/EBCP Committee Reviewers; Alston P, Fitzgerald D, Nikolic A, Onorati F, Rasmussen BS, Svenmarker S. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Br J Anaesth. 2019 Dec;123(6):713-757. doi: 10.1016/j.bja.2019.09.012. Epub 2019 Oct 2. No abstract available.

    PubMed 31585674
  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307-10.

    PubMed 2868172
  • Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989 Mar;45(1):255-68.

    PubMed 2720055
  • Banerjee et al. Beyond kappa : a review of interrater agreement measures. Can. J. Statistics 1999 ; 27 : 3 - 23.

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiac Surgical Procedures, run by Clinique du Millenaire.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Philippe BURTIN, MD (+33622745310, philippe.burtin@cegetel.net), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Extubation time (minutes) (time frame: 150 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04760340, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in